240 related articles for article (PubMed ID: 9261744)
1. HLA class II expression in well differentiated thyroid carcinoma: correlation with clinicopathological features.
Knoll MR; Schwab M; Oestreich K; Rumstadt B; Hagmüller E
J Exp Clin Cancer Res; 1997 Jun; 16(2):177-82. PubMed ID: 9261744
[TBL] [Abstract][Full Text] [Related]
2. Differences in tumor cell proliferation, HLA DR expression and lymphocytic infiltration in various types of thyroid carcinoma.
Lindhorst E; Schumm-Draeger PM; Bojunga J; Usadel KH; Herrmann G
Exp Clin Endocrinol Diabetes; 2002 Jan; 110(1):27-31. PubMed ID: 11835122
[TBL] [Abstract][Full Text] [Related]
3. Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance.
Hilders CG; Munoz IM; Nooyen Y; Fleuren GJ
Gynecol Oncol; 1995 Jun; 57(3):366-75. PubMed ID: 7774840
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size.
Cvejic DS; Savin SB; Petrovic IM; Paunovic IR; Tatic SB; Havelka MJ
Head Neck; 2005 Dec; 27(12):1049-55. PubMed ID: 16155918
[TBL] [Abstract][Full Text] [Related]
5. Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis.
Xu X; Quiros RM; Maxhimer JB; Jiang P; Marcinek R; Ain KB; Platt JL; Shen J; Gattuso P; Prinz RA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5968-79. PubMed ID: 14676122
[TBL] [Abstract][Full Text] [Related]
6. Clinical presentations and outcomes of surgical treatment of follicular variant of the papillary thyroid carcinomas.
Chang HY; Lin JD; Chou SC; Chao TC; Hsueh C
Jpn J Clin Oncol; 2006 Nov; 36(11):688-93. PubMed ID: 17000702
[TBL] [Abstract][Full Text] [Related]
7. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
Rivera M; Ghossein RA; Schoder H; Gomez D; Larson SM; Tuttle RM
Cancer; 2008 Jul; 113(1):48-56. PubMed ID: 18484584
[TBL] [Abstract][Full Text] [Related]
8. Expression and function of the chemokine receptor CCR7 in thyroid carcinomas.
Sancho M; Vieira JM; Casalou C; Mesquita M; Pereira T; Cavaco BM; Dias S; Leite V
J Endocrinol; 2006 Oct; 191(1):229-38. PubMed ID: 17065406
[TBL] [Abstract][Full Text] [Related]
9. Lymphocytic infiltration in pediatric thyroid carcinomas.
Van Savell H; Hughes SM; Bower C; Parham DM
Pediatr Dev Pathol; 2004; 7(5):487-92. PubMed ID: 15547772
[TBL] [Abstract][Full Text] [Related]
10. [Immunohistochemical studies of mononuclear cellular infiltrates of papillary, follicular and anaplastic thyroid cancers].
Kornfehl J; Wilfing A; Hermann M
Laryngorhinootologie; 1994 Apr; 73(4):183-8. PubMed ID: 8011021
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal immunohistochemical expression of sodium/iodide symporter and hexokinase I in primary thyroid tumors with synchronous cervical metastasis.
Jung YH; Hah JH; Sung MW; Kim KH; Cho SY; Jeon YK
Laryngoscope; 2009 Mar; 119(3):541-8. PubMed ID: 19235753
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas.
Furlan JC; Bedard YC; Rosen IB
J Am Coll Surg; 2004 Mar; 198(3):341-8. PubMed ID: 14992733
[TBL] [Abstract][Full Text] [Related]
13. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma.
Ryschich E; Nötzel T; Hinz U; Autschbach F; Ferguson J; Simon I; Weitz J; Fröhlich B; Klar E; Büchler MW; Schmidt J
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):498-504. PubMed ID: 15701833
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical study of type-1 blood antigen expressions in thyroid tumors: the significance for papillary carcinomas.
Kamoshida S; Ogane N; Yasuda M; Muramatsu T; Bessho T; Kajiwara H; Osamura RY
Mod Pathol; 2000 Jul; 13(7):736-41. PubMed ID: 10912932
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm.
Tabriz HM; Adabi Kh; Lashkari A; Heshmat R; Haghpanah V; Larijani B; Tavangar SM
Pathol Res Pract; 2009; 205(2):83-7. PubMed ID: 18996649
[TBL] [Abstract][Full Text] [Related]
16. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma.
Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A
Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634
[TBL] [Abstract][Full Text] [Related]
17. Regional metastases in well-differentiated thyroid carcinoma: pattern of spread.
Yanir Y; Doweck I
Laryngoscope; 2008 Mar; 118(3):433-6. PubMed ID: 18043490
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of the desmoplastic tumor stroma in medullary thyroid carcinoma.
Koperek O; Scheuba C; Puri C; Birner P; Haslinger C; Rettig W; Niederle B; Kaserer K; Garin Chesa P
Int J Oncol; 2007 Jul; 31(1):59-67. PubMed ID: 17549405
[TBL] [Abstract][Full Text] [Related]
19. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
20. Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters.
Redondo M; Concha A; Oldiviela R; Cueto A; Gonzalez A; Garrido F; Ruiz-Cabello F
Cancer Res; 1991 Sep; 51(18):4948-54. PubMed ID: 1654207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
